331646-99-2

Basic information

• Product Name: 8-bromoquinazoline-2,4(1H,3H)-dione
• Synonyms: 8-bromoquinazoline-2,4(1H,3H)-dione;8-Bromo-2,4(1H,3H)-quinazolinedione;2,4(1H,3H)-Quinazolinedione, 8-bromo-;8-Bromo-1H-quinazoline-2,4-dione;8-BROMO-2,4-DIHYDROXY QUINOZALINE
• CAS NO: 331646-99-2
• Molecular Formula: C₈H₅BrN₂O₂
• Molecular Weight: 241.0415
• Mol File: 331646-99-2.mol

Chemical Properties

• Boiling Point: 537.6 °C at 760 mmHg
• Flash Point: 278.9 °C
• Appearance: /
• Density: 1.959 g/cm³
• Vapor Pressure: 3.58E-12mmHg at 25°C
• Refractive Index: 1.782
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 10.29±0.20(Predicted)
• CAS DataBase Reference: 8-bromoquinazoline-2,4(1H,3H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 8-bromoquinazoline-2,4(1H,3H)-dione(331646-99-2)
• EPA Substance Registry System: 8-bromoquinazoline-2,4(1H,3H)-dione(331646-99-2)

Safety Data

• Hazardous Substances Data: 331646-99-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
8-Bromoquinazoline-2,4(1H,3H)-dione is used as an anticancer agent for its potential to target and inhibit the growth of cancer cells. Its biological activities have been studied, and it has shown promise in the development of treatments for various types of cancer.
Used in Chemical Industry:
8-Bromoquinazoline-2,4(1H,3H)-dione serves as a building block in the synthesis of more complex organic compounds. Its unique structure and functional groups make it a valuable component in the creation of new molecules with specific properties and applications in various chemical processes.
Used in Enzyme Inhibition:
8-Bromoquinazoline-2,4(1H,3H)-dione is used as an enzyme inhibitor, targeting specific enzymes involved in various biological processes. Its inhibitory effects have potential applications in the development of drugs for treating enzyme-related diseases and conditions.

InChI:InChI=1/C8H5BrN2O2/c9-5-3-1-2-4-6(5)10-8(13)11-7(4)12/h1-3H,(H2,10,11,12,13)

Upstream product

• 20776-51-6 2-amino-3-bromo benzoic acid 
• 57-13-6 urea 
• 20780-74-9 7-bromoisatin 
• 917-61-3 sodium isocyanate 
• 608-30-0 2,6-dibromoaniline 
• 124-38-9 carbon dioxide 
• 114344-60-4 2-amino-3-bromo-benzonitrile 

Downstream Products

• 331647-05-3 8-bromo-2,4-dichloroquinazoline 
• 1262431-79-7 8-[(2S,3S,4R,5R)-3,4-bis(benzyloxy)-5-[(benzyloxy)methyl]oxolan-2-yl]-2,4-dimethoxyquinazoline 
• 956100-62-2 8-bromo-2-chloroquinazolin-4-amine 
• 956100-63-3 8-bromo-2-chloroquinazoline 

Relevant articles and documents

Discovery of (R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3 H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies

Pim kinases are a family of constitutively active serine/threonine kinases that are partially redundant and regulate multiple pathways important for cell growth and survival. In human disease, high expression of the three Pim isoforms has been implicated in the progression of hematopoietic and solid tumor cancers, which suggests that Pim kinase inhibitors could provide patients with therapeutic benefit. Herein, we describe the structure-guided optimization of a series of quinazolinone-pyrrolodihydropyrrolone analogs leading to the identification of potent pan-Pim inhibitor 28 with improved potency, solubility, and drug-like properties. Compound 28 demonstrated on-target Pim activity in an in vivo pharmacodynamic assay with significant inhibition of BAD phosphorylation in KMS-12-BM multiple myeloma tumors for 16 h postdose. In a 2-week mouse xenograft model, daily dosing of compound 28 resulted in 33% tumor regression at 100 mg/kg.

COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME

The present invention discloses an organic compound and an organic electroluminescence device using the organic compound as a material in the light emitting layer of the organic electroluminescence device. The organic compound may be for lowering a driving voltage, power consumption or increasing a current efficiency or 90% life time of the organic electroluminescence device. The same definition as described in the present invention.

Discovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RAS

Proteins in the RAS family are important regulators of cellular signaling and, when mutated, can drive cancer pathogenesis. Despite considerable effort over the last 30 years, RAS proteins have proven to be recalcitrant therapeutic targets. One approach for modulating RAS signaling is to target proteins that interact with RAS, such as the guanine nucleotide exchange factor (GEF) son of sevenless homologue 1 (SOS1). Here, we report hit-to-lead studies on quinazoline-containing compounds that bind to SOS1 and activate nucleotide exchange on RAS. Using structure-based design, we refined the substituents attached to the quinazoline nucleus and built in additional interactions not present in the initial HTS hit. Optimized compounds activate nucleotide exchange at single-digit micromolar concentrations in vitro. In HeLa cells, these quinazolines increase the levels of RAS-GTP and cause signaling changes in the mitogen-activated protein kinase/extracellular regulated kinase (MAPK/ERK) pathway.

QUINAZOLINE COMPOUNDS AS MODULATORS OF RAS SIGNALING

The present invention relates to quinazoline compounds and compositions that modulate Ras signaling. Compounds and compositions of the present invention are useful in the treatment of cancers and other disease states associated with Ras dysfunction (e.g.,

CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF

Disclosed are a condensed-ring pyrimidylamino derivative, a preparation method therefor, and an intermediate, a pharmaceutical composition and applications thereof. The method for preparing the condensed-ring pyrimidylamino derivative comprises: in a solvent, in the presence of a palladium-containing catalyst, allowing a compound represented by formula I-a and a compound represented by formula I-b' to have a coupling reaction, and then preparing a compound represented by formula I by means of a deprotection reaction. Also disclosed applications of the condensed-ring pyrimidylamino derivative in the preparation of drugs for preventing, relieving and/or treating tumors or diseases caused by an anaplastic lymphoma kinase. The condensed-ring pyrimidylamino derivative of the present invention has an obvious restraint effect on the anaplastic lymphoma kinase.

FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF

Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.

Discovery of 5-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine as a Potent IKur Inhibitor

A new series of phenylquinazoline inhibitors of Kv 1.5 is disclosed. The series was optimized for Kv 1.5 potency, selectivity versus hERG, pharmacokinetic exposure, and pharmacodynamic potency. 5-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine (13k) was identified as a potent and ion channel selective inhibitor with robust efficacy in the preclinical rat ventricular effective refractory period (VERP) model and the rabbit atrial effective refractory period (AERP) model.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

The components of xRNA: Synthesis and fluorescence of a full genetic set of size-expanded ribonucleosides

The synthesis and properties of a full set of four benzo-expanded ribonucleosides (xRNA), analogous to A, G, C, and U RNA monomers, are described. The nucleosides are efficient fluorophores with emission maxima of 369-411 nm. The compounds are expected to